Dylan M. Zylla

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer

Ethan Basch, Deborah Schrag, Sydney Henson et al. · JAMA · 2022 · 383 citations · Full text

Pharmacy, Health Informatics, Oncology +17

Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer

Dylan M. Zylla, Brett L. Gourley, Derek Vang et al. · Cancer · 2013 · 194 citations · Full text

Medicine, Oncology, Pharmacology +15

Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer

Dylan M. Zylla, Michael A. Kuskowski, Kalpna Gupta et al. · British Journal of Anaesthesia · 2014 · 103 citations · Full text

Medicine, Oncology, Pharmacology +16

A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction

Dylan M. Zylla, Justin Eklund, Grace Gilmore et al. · Supportive Care in Cancer · 2021 · 64 citations

Medicine, Oncology, Pharmacotherapy +16